ImmuFact® IMP321 Chemo-Immunotherapy
The Company is seeking a partner to carry out the Phase IIb/III trial in first-line metastatic breast cancer leading to Conditional Marketing Authorisation and marketing. The partner will also initiate new studies in a wide range of cancers and different chemotherapies.
ImmuFact® IMP321 Vaccine Ajuvant
The Company is seeking partnerships to carry out clinical development of IMP321 as an adjuvant to proprietary cancer vaccines (completed or ongoing proof-of-concept trials in disease-free melanoma, metastatic melanoma and prostate cancer).